Barclays sets target for Ligand Pharmaceuticals stock at USD 345

Published on 10/20/2026 at 19:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Ligand reports third-quarter results on October 29, 2026. Ligand Pharmaceuticals stock costs EUR 276.00 on October 20, 2026 at 7:31 p.m. CEST.

Analyst target and reporting date

Barclays initiated coverage with an Overweight rating and a USD 345.00 price target on September 25, 2026.
Ligand Pharmaceuticals will report third-quarter 2026 results on October 29, 2026.
Ligand Pharmaceuticals stock costs EUR 276.00 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST.

LGND, US53220K5048, Illustration mit AI erstellt.

Ligand Pharmaceuticals stock is priced at EUR 276.00 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST. Barclays initiated coverage on September 25, 2026 with an Overweight rating and a USD 345.00 price target, according to Markets Insider.

Barclays sees royalty growth

The Barclays target is 11.39 percent above Ligand's Nasdaq price of USD 309.71 on October 20, 2026 at 1:33 p.m. ET. The company is building its business around royalty interests and licensing technologies rather than relying only on direct drug sales.

Ligand's portfolio includes economic interests in more than 200 development and commercial-stage assets, while its Captisol and NITRICIL technologies support drug development and formulation. The company described this model in its October 15, 2026 results-date release.

Second-quarter figures set the benchmark

For the second quarter of 2026, Ligand generated USD 83.70 million in revenue and adjusted earnings per share of USD 2.37, according to Investing.com. Revenue exceeded the cited USD 62.93 million consensus estimate, while adjusted earnings per share surpassed the USD 1.95 consensus estimate.

What comes next for valuation?

Ligand will report third-quarter 2026 results on October 29, 2026, with the call scheduled for 8:30 a.m. ET, according to the company's Ligand Pharmaceuticals release. The current Nasdaq price implies a price-to-earnings ratio of 33.06 and a market capitalization of USD 6.2 billion as of October 20, 2026.

Stock position and next date

The Nasdaq 52-week range is USD 175.89 to USD 326.63 as of October 20, 2026. The current USD 309.71 price is 5.18 percent below the high, leaving the upcoming results as the next scheduled company-specific date.

Current trading level

Ligand Pharmaceuticals is a biotechnology company listed on Nasdaq under LGND. Its euro quotation stood at EUR 276.00 at Lang & Schwarz on October 20, 2026 at 7:31 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Ligand Pharmaceuticals stock.